12-10-61

Date of Deposit:

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Donna T. Ward and Andrew T. Watt


For: Antisense Modulation of EIF2C1 Expression

BOX SEQUENCE

DDDYDYB . 1100D

Assistant Commissioner for Patents

Washington DC 20231



Transmitted herewith for filing, please find the following:

- · The specification of the above-referenced patent application;
- · An executed Declaration or Oath and Power of Attorney;
- · An Assignment of the invention to Isis Pharmaceuticals Inc. with recordation cover sheet (PTO Form PTO-1595) and \$40.00 cover fee;
- · Statement to Support Filing and Submission of DNA/Amino Acid Sequences in Accordance with 37 CFR § § 1.821 through 1.825;
- · Sequence listing in computer readable form in accordance with 37 C.F.R. § 1.821(e);
- · An Information Disclosure Statement with references; and

. Applicant claims small entity status pursuant to 37 CFR § 1.27.

The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Rate	Fee
BASE FEE			Sale of the sale of	\$370.00
Total Claims	20 - 20 =	0	X \$9=	\$0
Indep. Claims	2 - 3 =	0	x\$40=	\$0
TOTAL				\$ 370.00

The Commissioner is hereby authorized to charge the following fees to Deposit Account

- · the amount of \$410.00 for the above listed fees;
- · payment of the following fees associated with this communication or credit any overpayment;
- · any additional filing fees required under 37 CFR 1.16 including fees for presentation of extra claims; and
- · any additional patent application processing fees under 37 CFR 1.17 and under 37 CFR 1.20 (d).

Triplicate copies of this transmittal are enclosed.

Date: Movember & 2001

Donna T. Ward Registration No. 48,271 Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Jane Massev Licata or Kathleen A. Tyrrell

Licata & Tyrrell, P.C.

66 East Main Street Marlton NJ 08053

(856) 810-1515

1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor(s): Donna T. Ward and Andrew T. Watt

Serial No.: not yet assigned

Filing Date: herewith

Title: Antisense Modulation of EIF2C1 Expression

BOX SEQUENCE Assistant Commissioner for Patents Washington, D.C., 20231

STATEMENT TO SUPPORT FILING AND SUBMISSION IN ACCORDANCE WITH 37 C.F.R. §§ 1.821 THROUGH 1.825

I hereby state, in accordance with the requirements of 37 C.F.R. §1.821(f), that the contents of the paper and computer readable copies of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e), respectively, are the same.

Date: Navember 8, 2001

Respectfully submitted,

Donna T. Ward Registration No. 48,271 Isis Pharmaceuticals, Inc.

Please address all correspondence to:

Licata & Tyrrell, P.C. 66 East Main Street Marlton NJ 08053 (856) 810-1515